MedEquities Realty Trust (NYSE:MRT) had its price target trimmed by Canaccord Genuity from $13.00 to $12.00 in a research report report published on Thursday morning. The brokerage currently has an overweight rating on the financial services provider’s stock.

Several other research analysts have also weighed in on MRT. Zacks Investment Research raised MedEquities Realty Trust from a hold rating to a buy rating and set a $13.00 target price on the stock in a research report on Wednesday, July 25th. ValuEngine lowered MedEquities Realty Trust from a sell rating to a strong sell rating in a research report on Wednesday. JMP Securities set a $13.00 target price on MedEquities Realty Trust and gave the stock a buy rating in a research report on Friday, May 11th. B. Riley set a $13.00 target price on MedEquities Realty Trust and gave the stock a buy rating in a research report on Monday, May 14th. Finally, KeyCorp lowered MedEquities Realty Trust from an overweight rating to a hold rating and set a $12.00 target price on the stock. in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $12.22.

MedEquities Realty Trust traded down $0.21, hitting $9.96, during mid-day trading on Thursday, MarketBeat reports. The stock had a trading volume of 113,788 shares, compared to its average volume of 100,020. MedEquities Realty Trust has a 1-year low of $9.67 and a 1-year high of $12.05. The firm has a market cap of $324.04 million, a P/E ratio of 8.74 and a beta of -0.11.

MedEquities Realty Trust (NYSE:MRT) last issued its earnings results on Wednesday, August 8th. The financial services provider reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.20). MedEquities Realty Trust had a return on equity of 5.73% and a net margin of 30.84%. The firm had revenue of $17.56 million during the quarter, compared to analyst estimates of $17.03 million. sell-side analysts forecast that MedEquities Realty Trust will post 1.21 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 29th. Stockholders of record on Wednesday, August 15th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Tuesday, August 14th. This represents a $0.84 annualized dividend and a dividend yield of 8.43%. MedEquities Realty Trust’s dividend payout ratio (DPR) is presently 73.68%.

In other news, Director Bluemountain Capital Managemen sold 18,346 shares of the company’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $10.32, for a total transaction of $189,330.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 165,564 shares of company stock valued at $1,712,407. 2.50% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC bought a new stake in shares of MedEquities Realty Trust during the 4th quarter worth about $120,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of MedEquities Realty Trust during the 2nd quarter worth about $131,000. People s United Financial Inc. bought a new stake in shares of MedEquities Realty Trust during the 2nd quarter worth about $158,000. Bank of Montreal Can bought a new stake in shares of MedEquities Realty Trust during the 2nd quarter worth about $160,000. Finally, Barclays PLC boosted its stake in shares of MedEquities Realty Trust by 252.2% during the 1st quarter. Barclays PLC now owns 16,016 shares of the financial services provider’s stock worth $168,000 after acquiring an additional 11,469 shares in the last quarter. Institutional investors own 91.65% of the company’s stock.

MedEquities Realty Trust Company Profile

MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.

Further Reading: Should you buy a closed-end mutual fund?

Analyst Recommendations for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.